1 published article · Updated continuously
12 trials tracked for SARS-CoV Infection: 5 in phase 3 or 4 and 5 with published results. The most-cited published study has 1407 citations.
Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical trials evaluated several pharmacological interventions for the management of SARS-CoV infection. Losartan was studied across multiple trials; results showed a P/F ratio at 7 days of 281.4 vs 260.9, and ventilator-free days were recorded at 18.4 and 18.1 respectively 10. In another study involving Losartan, the hospitalization rate was reported as 5.2% versus 1.7%, with a physical composite score change of 1.4 vs 0.2 11.
Hydroxychloroquine was evaluated in large-scale trials. One study found no significant difference in the number of participants with active disease at day 14 (49 vs 58, p=0.35) or in changes to disease severity over 14 days (-2.6 vs -2.33, p=0.117) 2. Another trial using Hydroxychloroquine reported consistent scores on the COVID Ordinal Outcomes Scale at day 3 (4; 4) and day 8 (5; 6), with a score of 6 on the COVID Outcomes Scale at day 15 3.
Other established interventions included Metformin 4 and VERU-111 5.
AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
